Validation of a Molecular Prognostic Test for Eye Melanoma

This study has been withdrawn prior to enrollment.
(It has come to our attention that the site was not necessary for our research project.)
Sponsor:
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00406120
First received: November 29, 2006
Last updated: May 16, 2007
Last verified: May 2007
  Purpose

Up to half of patients with ocular melanoma (also called iris, choroidal or uveal melanoma) develop metastasis. We have found that certain molecular features of the eye tumor can be detected by gene expression profiling and accurately predict which patients will develop metastasis. This molecular test could eventually allow high risk patients to receive preventative therapy to delay or prevent the development of metastasis. The goal of this study is to prospectively validate the predictive accuracy of the gene expression-based molecular test and compare it to monosomy 3, the most common but potentially less accurate molecular marker for metastasis in ocular melanoma.


Condition Intervention
Uveal Neoplasms
Choroid Neoplasms
Iris Neoplasms
Procedure: Fine needle aspiration biopsy

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Validation of a Molecular Test for Predicting Metastasis in Patients With Uveal Melanoma

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Estimated Enrollment: 2000
Study Start Date: January 2007
Estimated Study Completion Date: December 2017
Detailed Description:

We have discovered a gene expression profile derived from primary uveal melanomas that accurately predicts which patients will develop metastasis. Tumors with a class 1 gene expression signature have a very low risk, and those with a class 2 signature have a high risk of metastasis. The molecular test was initially performed on tissue obtained from enucleated eyes using commercial microarray platforms. We are now able to perform the molecular test on fine needle biopsy specimens, and we have developed a customized test that has greater dynamic range and sensitivity than commercial microarray platforms. The goal of this study is to validate the prognostic accuracy of the customized platform by performing the molecular test on primary uveal melanomas obtained from enucleation, local tumor resection or fine needle biopsy. Each sample will be diagnosed as either class 1, class 2 or indeterminate. Outcomes will be collected and the ability of the molecular diagnosis to predict metastasis will be evaluated at regular intervals.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical diagnosis of melanoma of the iris, ciliary body and/or choroid
  • treatment to include enucleation, radiotherapy or local tumor resection

Exclusion Criteria:

  • evidence of marked tumor necrosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406120

Locations
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: J. William Harbour, MD Washington University Early Recognition Center
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00406120     History of Changes
Other Study ID Numbers: 98-0042-A
Study First Received: November 29, 2006
Last Updated: May 16, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:
eye
uvea
iris
choroid
ciliary body
melanoma
iris melanoma
choroidal melanoma
ciliary body melanoma
uveal melanoma
posterior uveal melanoma
prognosis
metastasis
genetic testing
molecular testing
gene expression profiling

Additional relevant MeSH terms:
Neoplasms
Choroid Neoplasms
Iris Neoplasms
Melanoma
Uveal Neoplasms
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Choroid Diseases
Uveal Diseases
Iris Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on July 26, 2014